ArticleSAGE open medical case reports2026
Marginal zone lymphoma presenting with chylous ascites: A rare clinical manifestation and successful treatment with orelabrutinib-rituximab.
Article in SAGE open medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Marginal zone lymphoma is the second most common subtype of indolent non-Hodgkin lymphoma. Its clinical manifestations are heterogeneous and largely determined by the involved site. Chylous ascites, as the initial presentation of marginal zone lymphoma, is extremely rare. We report a 79-year-old man who presented with rapidly progressive abdominal distension due to high-volume chylous ascites. Flow cytometry of the ascitic fluid revealed a monoclonal lambda-restricted B-cell population consistent with low-grade B-cell lymphoma. Bone marrow biopsy confirmed splenic marginal zone lymphoma. Initial rituximab monotherapy was ineffective; however, combination therapy with orelabrutinib and rituximab led to complete resolution of ascites after two cycles and marked disease control. At 6-month follow-up, the patient remained in remission. Clinicians should consider lymphoma in the differential diagnosis of unexplained chylous ascites. Prompt etiologic treatment can result in favorable outcomes even in elderly patients with advanced disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.